Sarraf Pasha's Form 4 filing
Cue Biopharma, Inc. (CUE) · filed Jan 2, 2026
- Accession no.
- 0001193125-26-000900
- Filed
- Jan 2, 2026, 4:00 PM ET
- Trade date
- Dec 30, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $99.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sarraf PashaCIK 0002059447 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Common Stock | PPurchaseAcquired | +4,229 | $0.3094 | +$1,308.45 | 4,229 | Direct | |
| Dec 30, 2025 | Common Stock | PPurchaseAcquired | +77,148 | $0.3003 | +$23,167.54 | 81,377 | Direct | |
| Dec 30, 2025 | Common Stock | PPurchaseAcquired | +86,947 | $0.3174 | +$27,596.98 | 168,324 | Direct | |
| Dec 30, 2025 | Common Stock | PPurchaseAcquired | +78,116 | $0.3114 | +$24,325.32 | 246,440 | Direct | |
| Dec 30, 2025 | Common Stock | PPurchaseAcquired | +77,417 | $0.3016 | +$23,348.97 | 323,857 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.